Curcumin augments therapeutic efficacy of TRAIL-based immunotoxins in leukemia.

Pharmacological Reports : PR
Sridevi SurapallyRama Shanker Verma

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) has been perceived as a promising anti-cancer agent because of its unique ability to kill cancer cells while sparing normal cells. However, translation of TRAIL to clinical studies was less successful as a large number of cancer cells acquire resistance to TRAIL-based monotherapies. An ideal strategy to overcome TRAIL resistance is to combine it with potential sensitizing agents. To investigate the TRAIL-sensitizing effect of curcumin in leukemia. The mechanism underlying TRAIL sensitization by curcumin was studied by flow cytometric analysis of TRAIL receptors in leukemic cell lines and patient samples, and immunoblot detection of TRAIL-apoptosis signaling proteins. Curcumin augments TRAIL-apoptotic signaling in leukemic cells by upregulating the expression of DR4 and DR5 along with suppression of cFLIP and anti-apoptotic proteins Mcl-1, Bcl-xl, and XIAP. Curcumin pre-treatment significantly (p < 0.01) enhanced the sensitivity of leukemic cell lines to TRAIL recombinant proteins. IL2-TRAIL peptide in the presence of curcumin induced potent apoptosis (p < 0.001) as compared to TRAIL and IL2-TRAIL protein in leukemic cell lines with IC50 < 0.1 μΜ. Additionally...Continue Reading

References

Nov 25, 2003·Oncogene·Shulin Wang, Wafik S El-Deiry
Nov 20, 2004·Cancer Gene Therapy·Lidong Zhang, Bingliang Fang
Oct 15, 2005·Leukemia·S H Kaufmann, D P Steensma
Feb 28, 2006·Apoptosis : an International Journal on Programmed Cell Death·A R HussainS Uddin
Aug 8, 2006·Molecular Cancer Therapeutics·Jinrong ChengElizabeth A Repasky
Sep 2, 2006·American Journal of Hematology·Peter C EverettAdam Lerner
Oct 10, 2006·The AAPS Journal·Rajesh L ThangapazhamRadha K Maheshwari
Apr 3, 2008·Cancer Research·Seok-Hyun KimWafik S El-Deiry
Jul 11, 2009·The AAPS Journal·Jayaraj RavindranBharat B Aggarwal
Mar 4, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey WiezorekJonathan Graves
Jun 10, 2010·Oncogene·F Gonzalvez, A Ashkenazi
Jan 12, 2012·Molecular Cancer Therapeutics·Christian T Hellwig, Markus Rehm
Jan 11, 2013·BioFactors·Adeeb ShehzadYoung Sup Lee
Jul 13, 2013·Molecular and Cellular Biochemistry·Sojung ParkInki Kim
Jun 21, 2014·Cell Death and Differentiation·J LemkeH Walczak
Apr 18, 2015·Frontiers in Oncology·Rachana Trivedi, Durga Prasad Mishra
May 18, 2016·Journal of Clinical and Diagnostic Research : JCDR·Bushra IqbalSunita Tiwari
Oct 30, 2016·Anticancer Research·Y I DengRamin Rohanizadeh
Nov 12, 2016·Nutrients·Aline Renata PavanJean Leandro Dos Santos
Jan 12, 2017·Stem Cell Research·Jayaprakasam MadhumathiRama Shanker Verma
May 27, 2017·Archiv der Pharmazie·Márió GyurisLászló G Puskás
Jul 7, 2017·Clinical Science·Ajaikumar B KunnumakkaraBharat B Aggarwal
Oct 11, 2017·International Journal of Molecular Sciences·Gábor J SzebeniLászló G Puskás
Sep 28, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Raedeh SaraeiSaeed Solali

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.